DUBLIN--(BUSINESS WIRE)--The "Macular Edema - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Macular Edema - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 7 and 2 respectively.
Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Macular Edema - Overview
- Macular Edema - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Macular Edema - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Macular Edema - Companies Involved in Therapeutics Development
- ActiveSite Pharmaceuticals Inc
- Coherus BioSciences Inc
- Lupin Ltd
- Mabion SA
- OMEICOS Therapeutics GmbH
- Promedior Inc
- Taiwan Liposome Company Ltd
- Xbrane Biopharma AB
For more information about this report visit https://www.researchandmarkets.com/research/355fxt/macular_edema?w=4
